News stories about Dynatronics (NASDAQ:DYNT) have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Dynatronics earned a news sentiment score of 0.19 on Accern’s scale. Accern also gave news articles about the medical equipment provider an impact score of 46.3083154954286 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Separately, Zacks Investment Research raised Dynatronics from a “hold” rating to a “buy” rating and set a $3.50 price objective for the company in a research report on Monday, January 8th.
NASDAQ DYNT opened at $2.85 on Friday. Dynatronics has a one year low of $2.10 and a one year high of $3.75. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.83 and a current ratio of 1.62.
Dynatronics Company Profile
Dynatronics Corporation designs, manufactures, distributes, and markets physical medicine products in the United States and internationally. It manufactures and sells electrotherapy, therapeutic ultrasound, phototherapy, thermal therapy, iontophoresis devices, and other modalities; traction therapy equipment; and medical supplies and soft goods, including hot and cold packs, lumbar rolls, exercise balls, wrist splints, ankle weights, cervical collars and pillows, slings, bolsters, positioning wedges, back cushions, weight racks, rehabilitation products, back and wrist braces.
Receive News & Ratings for Dynatronics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynatronics and related companies with MarketBeat.com's FREE daily email newsletter.